Europas førende søgning efter kliniske forsøg

ANGIOTENSIN II

Clinical trials of ANGIOTENSIN II are studying how it may help in different serious hospital conditions. The trials look at safety and effectiveness in adults and children with acute kidney injury, liver cancer, and life-threatening low blood pressure. They also measure how well it works compared with standard treatment.

Table of contents

Overview of the trials

The trial data show three interventional studies of ANGIOTENSIN II in very different patient groups.[1][2][3] These studies are authorised and include a low-intervention study, a Phase 2 study, and a Phase 3 study.[1][2][3]

The trials are designed to test whether ANGIOTENSIN II can improve important clinical outcomes in patients with acute kidney injury, liver cancer, and refractory hypotension in distributive shock.[1][2][3]

Trial in acute kidney injury after cardiac surgery

One study is titled “Reduction of occurence of Acute Kidney Injury through administration of angiotensin II versus Noradrenaline” and is registered as NCT06615102.[1] It is an interventional, low-intervention trial with 1,022 participants and status Authorised.[1]

This trial studies adults with acute kidney injury after cardiac surgery and asks whether ANGIOTENSIN II, used as the primary vasopressor, can reduce the occurrence of moderate or severe kidney injury within 72 hours after surgery.[1] The comparison treatment is noradrenaline, which is another blood-pressure medicine used in the study.[1]

The main outcome is the rate of AKI KDIGO stage 2 or 3 or death within 72 hours after cardiac surgery.[1] KDIGO is a kidney injury grading system, and stage 2 or 3 means more serious kidney damage.[1]

Trial in liver cancer and radioembolization

Another study is the RADIANT study, registered as 2025-521870-33-00.[2] It is a Phase 2 interventional trial with 15 participants and status Authorised.[2]

This trial includes patients with liver cancer, either primary or secondary, and studies ANGIOTENSIN II during radioembolization, which is a treatment that delivers radiation inside the liver blood vessels.[2] In this study, ANGIOTENSIN II is given intra-arterially, meaning directly into an artery.[2]

The main question is whether ANGIOTENSIN II improves the tumor-to-non-tumor ratio after treatment with 90Y glass microspheres compared with the ratio seen after 99mTc-MAA without ANGIOTENSIN II.[2] In simple words, the researchers want to know if more of the treatment reaches the tumor and less reaches normal tissue.[2]

Trial in children with life-threatening low blood pressure

The third study is registered as 2025-523750-14-00 and is a Phase 3 interventional trial with 143 participants.[3] It is authorised and studies patients aged 0–17 years with refractory hypotension in distributive shock.[3]

This trial compares ANGIOTENSIN II with placebo while children are already receiving fluid resuscitation and standard-of-care vasopressors.[3] The study is designed to see whether ANGIOTENSIN II can lower the amount of standard blood-pressure medicine needed.[3]

The main outcome is the change in the dose of standard-of-care vasopressors, measured as norepinephrine base equivalent dose from baseline to the first 6 hours of treatment.[3] This tells researchers whether the study medicine helps reduce the need for other blood-pressure support.[3]

Main outcomes and what they mean

Each trial uses a different endpoint, which means the main result the researchers want to measure.[1][2][3]

  • In the kidney study, the endpoint is whether a patient develops stage 2 or 3 acute kidney injury or dies within 72 hours after cardiac surgery.[1]

  • In the liver cancer study, the endpoint is the improvement factor in tumor-to-non-tumor ratio after radioembolization.[2]

  • In the pediatric shock study, the endpoint is the change in vasopressor dose during the first 6 hours of treatment.[3]

These endpoints show that the trials are not just looking at whether ANGIOTENSIN II can be given, but whether it changes important patient outcomes.[1][2][3]

Who may take part

The trial populations are very specific, and each study focuses on a different group of patients.[1][2][3]

  • Adults after cardiac surgery who are at risk of acute kidney injury can be included in the kidney study.[1]

  • Patients with primary or secondary liver cancer can be included in the RADIANT study.[2]

  • Children and teenagers aged 0–17 years with refractory hypotension in distributive shock can be included in the Phase 3 pediatric study.[3]

Because the studies are in different conditions and age groups, the entry rules are not the same across trials.[1][2][3]

Trial ID Phase Condition studied Status Enrollment
NCT06615102 Low Intervention Acute kidney injury Authorised 1022
2025-521870-33-00 Phase 2 Liver cancer (primary or secondary) Authorised 15
2025-523750-14-00 Phase 3 Refractory hypotension in distributive shock Authorised 143

FAQ

  • What are clinical trials of ANGIOTENSIN II trying to find out? They are testing whether ANGIOTENSIN II can improve outcomes in serious conditions such as acute kidney injury, liver cancer, and refractory hypotension in distributive shock. The trials measure results like kidney injury rates, treatment effect in liver procedures, and changes in vasopressor dose.
  • Who can take part in these trials? The trials include different groups: adults after cardiac surgery with risk of acute kidney injury, patients with primary or secondary liver cancer, and children aged 0–17 years with life-threatening low blood pressure. Each study has its own entry rules.
  • What phases are the ANGIOTENSIN II trials in? The trial data include a Phase 2 study, a Phase 3 study, and one low-intervention study. This means the research is at different stages, from early testing to larger confirmation studies.
  • What conditions are being studied? The studies focus on acute kidney injury after cardiac surgery, liver cancer, and refractory hypotension in distributive shock. These are serious conditions treated in hospital settings.
  • How do these trials measure success? They use clinical endpoints, which are the main results the researchers want to track. Examples include the rate of moderate or severe kidney injury or death, improvement in tumor-to-non-tumor ratio, and change in vasopressor dose over the first 6 hours.

Igangværende kliniske forsøg for ANGIOTENSIN II

  • Undersøgelse af angiotensin II ved radioembolisering for at forbedre tumor-absorberet dosis hos patienter med primær eller sekundær leverkræft

    Rekrutterer

    1 1 1
    Undersøgte sygdomme:
    Undersøgte lægemidler:
    Holland

  • Sammenligning af angiotensin II og noradrenalin til forebyggelse af akut nyreskade efter hjerteoperation

    Rekrutterer

    1 1 1 1
    Undersøgte sygdomme:
    Undersøgte lægemidler:
    Tyskland

  • Angiotensin II til børn og unge fra 0 til 17 år med behandlingsresistent hypotension ved distributivt shock

    Rekrutterer endnu ikke

    1 1 1
    Undersøgte sygdomme:
    Undersøgte lægemidler:
    Frankrig Tyskland Italien Spanien

Ordliste

  • Acute kidney injury (AKI): A sudden loss of kidney function. In these trials, researchers look at whether ANGIOTENSIN II can lower the chance of moderate or severe AKI.
  • Cardiac surgery: An operation on the heart. One trial studies patients after this type of surgery.
  • Vasopressor: A medicine used to raise blood pressure. The trials compare ANGIOTENSIN II with standard vasopressors or use it as part of treatment.
  • Refractory hypotension: Blood pressure that stays dangerously low even after usual treatment. One trial studies children with this problem.
  • Distributive shock: A life-threatening condition where blood vessels are too wide, causing very low blood pressure and poor blood flow.
  • Standard-of-care (SOC): The usual treatment that doctors already use. In one study, ANGIOTENSIN II is tested against placebo on top of standard care.
  • Placebo: A look-alike treatment with no active medicine. It helps show whether the study medicine truly works.
  • Phase 2: An earlier study phase that helps researchers learn more about whether a treatment may work and how to measure its effect.
  • Phase 3: A larger study phase used to confirm whether a treatment works in a bigger group of patients.
  • Tumor-to-non-tumor ratio (TNR): A measurement that compares how much treatment reaches the tumor versus nearby normal tissue. One liver cancer study uses this as its main outcome.
  • Norepinephrine base equivalent dose (NED): A way to measure the total amount of blood-pressure medicine being used. One pediatric study tracks changes in this dose.

Referencer

  1. https://kliniske-forsoeg.dk/forsog/sammenligning-af-angiotensin-ii-og-noradrenalin-til-forebyggelse-af-akut-nyreskade-efter-hjerteoperation/
  2. https://clinicaltrials.gov/study/2025-521870-33-00
  3. https://clinicaltrials.gov/study/2025-523750-14-00